Gene · 1999
Papers2,176
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,176
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Anticancer Effect of E26 Transformation-Specific Homologous Factor through the Induction of Senescence and the Inhibition of Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells. | Cancers (Basel) | 2023 | 37958443 | PubTator, text mining | PubMed |
| TJP3 promotes T cell immunity escape and chemoresistance in breast cancer: a comprehensive analysis of anoikis-based prognosis prediction and drug sensitivity stratification. | Aging (Albany NY) | 2023 | 37950731 | PubTator, text mining | PubMed |
| Essential procedures of single-cell RNA sequencing in multiple myeloma and its translational value. | Blood Sci | 2023 | 37941914 | PubTator, text mining | PubMed |
| Single-cell RNA-seq public data reveal the gene regulatory network landscape of respiratory epithelial and peripheral immune cells in COVID-19 patients. | Front Immunol | 2023 | 37936693 | PubTator, text mining | PubMed |
| Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling. | Cell Rep | 2023 | 37922311 | PubTator, text mining | PubMed |
| Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer. | NPJ Precis Oncol | 2023 | 37919480 | PubTator, text mining | PubMed |
| KRT19 is a Promising Prognostic Biomarker and Associates with Immune Infiltrates in Serous Ovarian Cystadenocarcinoma. | Int J Gen Med | 2023 | 37916194 | PubTator, text mining | PubMed |
| Epigenetic regulation during cancer transitions across 11 tumour types. | Nature | 2023 | 37914932 | PubTator, text mining | PubMed |
| Atg8ylation as a host-protective mechanism against Mycobacterium tuberculosis. | Front Tuberc | 2023 | 37901138 | PubTator, text mining | PubMed |
| Mutations in a High-Grade Micropapillary Urothelial Carcinoma of the Renal Pelvis: A Case Report. | Case Rep Oncol | 2023 | 37900819 | PubTator, text mining | PubMed |
| Ultrasound-Driven Healing: Unleashing the Potential of Chondrocyte-Derived Extracellular Vesicles for Chondrogenesis in Adipose-Derived Stem Cells. | Biomedicines | 2023 | 37893208 | PubTator, text mining | PubMed |
| The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers. | Biomolecules | 2023 | 37892233 | PubTator, text mining | PubMed |
| Multi-omics characteristics of tumor-associated macrophages in the tumor microenvironment of gastric cancer and their exploration of immunotherapy potential. | Sci Rep | 2023 | 37880233 | PubTator, text mining | PubMed |
| Single-nucleus RNA sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma. | EBioMedicine | 2023 | 37879219 | PubTator, text mining | PubMed |
| FOXA2 Suppression by TRIM36 Exerts Anti-Tumor Role in Colorectal Cancer Via Inducing NRF2/GPX4-Regulated Ferroptosis. | Adv Sci (Weinh) | 2023 | 37875418 | PubTator, text mining | PubMed |
| Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer. | Clin Cancer Res | 2023 | 37870965 | PubTator, text mining | PubMed |
| A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge. | Front Immunol | 2023 | 37869008 | PubTator, text mining | PubMed |
| Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. | Orphanet J Rare Dis | 2023 | 37865771 | PubTator, text mining | PubMed |
| Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures. | Front Immunol | 2023 | 37849766 | PubTator, text mining | PubMed |
| Cartilage oligomeric matrix protein overexpression is an independent poor prognostic indicator in patients with intrahepatic cholangiocarcinoma. | Sci Rep | 2023 | 37838792 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1999/papers?page=12